[144] Kura Oncology, Inc. SEC Filing

Rhea-AI Filing Summary

Kura Oncology (KURA) filed a Form 144 reporting a proposed sale of 6,892 shares of common stock through Morgan Stanley Smith Barney LLC on 09/29/2025. The filing lists the aggregate market value of the shares as $62,372.60 and indicates 87,015,518 shares outstanding. The securities were acquired as PSUs from the issuer on 09/27/2025, with payment noted on 09/29/2025. The filer reported no securities sold in the past three months and certified they are unaware of undisclosed material adverse information. Other filer contact fields in the form are present but contain no substantive names or contact details.

Positive

• Complete transaction details are provided: class, broker, number of shares, acquisition and sale dates, and aggregate market value
• No sales in past three months reported for the selling person, simplifying aggregation considerations under Rule 144

Negative

• Contact and filer identification fields in the provided extract lack substantive names or details
• Limited context: the filing does not include signature block or explicit filer identity in the excerpt provided

Insights

Securities Analyst

TL;DR Routine insider sale notice: small transaction relative to outstanding shares, appears procedural following PSU acquisition.

The Form 144 documents a proposed resale of 6,892 shares valued at $62,372.60 via Morgan Stanley Smith Barney on 09/29/2025. The shares were acquired as performance stock units two days earlier on 09/27/2025. With 87,015,518 shares outstanding, the filing reflects a de minimis transfer representing approximately 0.0079% of the outstanding float (calculated from provided numbers). The filing notes no prior sales in the preceding three months and includes the standard certification about material information.

Corporate Governance Expert

TL;DR Disclosure appears compliant with Rule 144 requirements; no red flags in the limited data provided.

The notice includes required elements: class of security, broker identity, acquisition date and nature (PSU), sale date, aggregate value, and outstanding shares. The signer affirms lack of undisclosed material information. Several contact fields are blank in the provided extract, but the essential transaction details for Rule 144 compliance are present in the content supplied.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6892	62372.6	87015518	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/27/2025	PSU	Issuer			6892	09/29/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the KURA Form 144 report say about the proposed sale?

The filing reports a proposed sale of 6,892 shares of common stock through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $62,372.60.

How and when were the shares being sold acquired according to the filing?

The shares were acquired as performance stock units (PSUs) from the issuer on 09/27/2025, with payment dated 09/29/2025.

Does the Form 144 indicate prior sales by the seller in the last three months?

No. The filing explicitly states: Nothing to Report for securities sold during the past three months.

What broker is handling the proposed sale listed in the filing?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza 8th Floor, New York, NY 10004.

How large is this proposed sale relative to Kura Oncology's outstanding shares?

The filing shows 87,015,518 shares outstanding; the proposed sale of 6,892 shares is a very small fraction of outstanding shares based on the numbers provided.